Jump to Main Contents
ncc en

Home > Information > press release > National Cancer Center and Carna Biosciences Announce Research Collaboration for new drug discovery

National Cancer Center and Carna Biosciences Announce Research Collaboration for new drug discovery

May 7, 2018
National Cancer Center
Carna Biosciences, Inc.
in  Japanese

National Cancer Center (Tokyo Japan, President: Hitoshi Nakagama) and Carna Biosciences, Inc (Kobe Japan, President and CEO: Kohichiro Yoshino) announced today that they have entered into a research collaboration agreement to discover novel therapeutic interventions in cancers.
Under the agreement, National Cancer Center and Carna Biosciences will collaborate on drug discovery research to develop a novel anticancer drug with new mechanisms of action that have been discovered by Dr. Kenkichi Masutomi, Chief, Division of Cancer Stem Cell at National Cancer Center Research Institute. During the research term, both parties will leverage their respective expertise, including Carna’s extensive expertise in small molecule drug discovery with its powerful drug discovery engine and National Cancer Center’s profound knowledge of cancer research.

National Cancer Center and Carna Biosciences have been working together successfully under a research collaboration since 2008 to research and develop new drugs targeting WNT signal. This new collaboration agreement will further strengthen the relationship between both parties, which enables to accelerate the development of novel anti-cancer drugs to bring innovative treatment to cancer patients.

About National Cancer Center

National Cancer Center, founded in 1962, is a leading medical institute in Japan for treatment and research of cancer. The center has been actively engaged in investigator initiated clinical studies and clinical research, producing a number of research results that lead to drug discovery.

About Carna Biosciences

Carna Biosciences is a biopharmaceutical company focused on the discovery and development of small molecule drugs to address serious unmet medical needs in oncology, autoimmune and inflammatory diseases, and neurological diseases.


National Cancer Center
Office of Public Relations, Strategic Planning Bureau
5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
E-mail: ncc-admin●ncc.go.jp(replace ● to @)

Carna Biosciences, Inc.
Corporate Planning
1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan
E-mai: ir-team●carnabio.com(replace ● to @)


Get Adobe Reader

In order to view PDF files, you need Adobe Reader. If you do not have Adobe Reader, please free download from the link destination in banner.